SCHEMBL5226935

SCHEMBL5226935

Cc1nc(-c2ccc(-c3ccc(CNCc4cccc(-n5cccn5)c4)cc3)cc2)no1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
MAPT P10636 1/20 0.40
FFAR4 Q5NUL3 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MPO P05164 2/20 0.38
DGAT2 Q96PD7 1/20 0.38
MAPK1 P28482 1/20 0.38
SCN9A Q15858 3/20 0.38
HDAC1 Q13547 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
KLKB1 P03952 1/20 0.37
KLK1 P06870 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TRPV3 Q8NET8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6563104 0.74 L3MBTL1 (0.62) L3MBTL1MAPTFFAR4MAPK1HDAC1
SCHEMBL5222506 0.73 L3MBTL1 (0.43) LMNAL3MBTL1MAPTMPOHDAC1
SCHEMBL30245937 0.71 DGAT2 (0.53) LMNAMAPTKDM4EDGAT2HDAC1
SCHEMBL25426507 0.71 DGAT2 (0.53) LMNAMAPTKDM4EDGAT2HDAC1
SCHEMBL5225416 0.71 L3MBTL1 (0.43) LMNAL3MBTL1MAPTHDAC1HDAC8
SCHEMBL13452467 0.71 LMNA (0.57) LMNAPI4KBMAPTKDM4EMPO
SCHEMBL13488645 0.70 S1PR1 (0.50) LMNAL3MBTL1MAPTHDAC1KLKB1
SCHEMBL5222143 0.70 HDAC1 (0.48) LMNAL3MBTL1MPOHDAC1HDAC8
SCHEMBL15021326 0.69 ERCC1 (0.52) LMNAL3MBTL1PI4KBMAPTFFAR4
SCHEMBL5222368 0.69 RAB9A (0.45) L3MBTL1MAPTKDM4EHDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP claimed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO claimed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US claimed
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP disclosed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO disclosed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019998-A1 Histamine-3 receptor antagonist HRH3, HRH4, HRH2 LMNA 4508/4885L3MBTL1 4112/4885PI4KB 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.